"Mutation" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
Descriptor ID |
D009154
|
MeSH Number(s) |
G05.365.590
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Mutation".
Below are MeSH descriptors whose meaning is more specific than "Mutation".
This graph shows the total number of publications written about "Mutation" by people in this website by year, and whether "Mutation" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 25 | 39 | 64 |
1995 | 25 | 47 | 72 |
1996 | 35 | 45 | 80 |
1997 | 33 | 58 | 91 |
1998 | 39 | 72 | 111 |
1999 | 39 | 103 | 142 |
2000 | 35 | 102 | 137 |
2001 | 39 | 100 | 139 |
2002 | 47 | 129 | 176 |
2003 | 47 | 150 | 197 |
2004 | 54 | 142 | 196 |
2005 | 56 | 167 | 223 |
2006 | 59 | 177 | 236 |
2007 | 83 | 173 | 256 |
2008 | 74 | 165 | 239 |
2009 | 78 | 168 | 246 |
2010 | 63 | 176 | 239 |
2011 | 100 | 187 | 287 |
2012 | 96 | 177 | 273 |
2013 | 90 | 208 | 298 |
2014 | 142 | 202 | 344 |
2015 | 139 | 224 | 363 |
2016 | 160 | 221 | 381 |
2017 | 128 | 278 | 406 |
2018 | 139 | 247 | 386 |
2019 | 126 | 250 | 376 |
2020 | 73 | 287 | 360 |
2021 | 90 | 250 | 340 |
2022 | 3 | 268 | 271 |
2023 | 2 | 229 | 231 |
2024 | 73 | 158 | 231 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mutation" by people in Profiles.
-
Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer. Pharmacoepidemiol Drug Saf. 2024 12; 33(12):e70049.
-
Testosterone acts through the membrane protein GPRC6A to cause cardiac edema in zebrafish embryos. Development. 2024 Dec 01; 151(23).
-
A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort. Blood. 2024 Nov 28; 144(22):2360-2363.
-
ClC-Kb pore mutation disrupts glycosylation and triggers distal tubular remodeling. JCI Insight. 2024 Nov 22; 9(22).
-
Redefining pancreatic cancer management with tumor-agnostic precision medicine. Carcinogenesis. 2024 Nov 22; 45(11):836-844.
-
Genomic Alterations in DNA Mismatch Repair Genes Across Different Cancer Types. JCO Precis Oncol. 2024 Nov; 8:e2400419.
-
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine. Blood. 2024 Nov 21; 144(21):2211-2222.
-
What have we learned about TP53-mutated acute myeloid leukemia? Blood Cancer J. 2024 Nov 19; 14(1):202.
-
Epigenome Reprogramming Through H3K27 and H3K4 Trimethylation as a Resistance Mechanism to DNA Methylation Inhibition in BRAFV600E-Mutated Colorectal Cancer. Clin Cancer Res. 2024 Nov 15; 30(22):5166-5179.
-
Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis. J Hematol Oncol. 2024 Nov 15; 17(1):112.